Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Trial Details

NCT ID
NCT06846606
Phase
PHASE1
Sponsor
Auron Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • AUTX-703
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Tampa, Florida, United States|27.94752,-82.45843
  • Buffalo, New York, United States|42.88645,-78.87837
  • New York, New York, United States|40.71427,-74.00597
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Participant must be ≥18 years of age
  • Participant must have confirmed diagnosis as follows:
  • R/R AML and has not achieved adequate response to, or cannot tolerate, all approved therapies known to be active for treatment of their disease OR …
  • Participant must be willing and able to comply with scheduled study visits and treatment plans.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →